Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales (Q47786014)

5 February 2018

title

Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales (English)

1 reference

5 February 2018

author name string

Ruth E Brown

1

1 reference

5 February 2018

Sean Stern

2

1 reference

5 February 2018

Sujith Dhanasiri

3

1 reference

5 February 2018

Steve Schey

4

1 reference

5 February 2018

publication date

10 May 2012

1 reference

5 February 2018

The European Journal of Health Economics

published in

1 reference

5 February 2018

volume

14

1 reference

5 February 2018

issue

3

1 reference

5 February 2018

page(s)

507-514

1 reference

5 February 2018

Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Cost-effectiveness of lenalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Pharmacoeconomic analyses using discrete event simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Health state utilities for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Racial differences in patients' perceptions of debilitated health states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0395-6

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22572968

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Valuing health-related quality of life in diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22572968

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10198-012-0395-6

1 reference

5 February 2018

1 reference

5 February 2018